ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO175

Associations Between Undercarboxylated Osteocalcin and Peripheral Vascular Calcification in CKD5

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Khairallah, Pascale, Columbia University Medical Center, New York, New York, United States
  • Fusaro, Maria, National Research Council (CNR) e Institute of Clinical Physiology (IFC), Pisa, Italy
  • Aghi, Andrea, Nephrology Unit, University of Padua, Padova, Italy
  • Plebani, Mario, Laboratory Medicine Unit, Department of Medicine, University of Padova, Padova, Italy
  • Zaninotto, Martina, University Hospital, Padova, Italy
  • Cosma, Chiara, University Hospital, Padova, Italy
  • Agarwal, Sanchita, Columbia University, New York, New York, United States
  • Aponte Farias, Maria A., Columbia University Medical Center, New York, New York, United States
  • Cortez, Natalia Erika, University of California, Davis, Davis, California, United States
  • Tripepi, Giovanni, IFC-CNR, Calabria, Italy
  • Nickolas, Tom, Columbia University Medical Center, New York, New York, United States
Background

Increasing evidence proposes a link between bone and vasculature in CKD. Osteocalcin (OCN) is the most abundant non-collagenous peptide found in the mineralized bone matrix. In vitamin K deficiency, such as advanced CKD and dialysis, OCN is predominantly in the undercarboxylated form (ucOCN). We hypothesized that ucOCN levels are associated with peripheral VC in patients with advanced CKD.

Methods

We studied 34 patients with CKD5-5D. Radial artery (RA) and Tibial artery (TA) VC were quantified by high-resolution peripheral computed tomography (HRpQCT), a validated tool to assess VC. Using specialized assays, we measured total OCN (LIASON® Osteocalcin Assay 310950 DiaSorin Inc., Stillwater MN, USA) and ucOCN (Glu-OC EIA Kit MK118 Takara Bio Inc., Otsu, Shiga, Japan). Spearman correlation analysis determined relationships between uc- and total circulating OCN and VCs.

Results


Our cohort had a mean+/-SD age of 48+/-14 years, 32% were female and 97% were Caucasian. Higher levels of ucOCN were associated with: (1) the presence of VC at the radius (r=0.4, p=0.03) but not at the tibia (r=0.3, p=0.06); and (2) greater severity of VCs at the TA (r=0.4, p=0.04) but not at the RA (r=0.3, p=0.07). Total OCN was not associated with either the presence of RA or TA VCs (p=0.1 and p=0.2 respectively) or the severity of RA and TA VCs (p=0.1 and p=0.3 respectively).

Conclusion

ucOCN is associated with the presence and severity of peripheral VC in patients with advanced CKD. This association has not been previously described in the literature. Larger studies are needed to confirm and determine mechanisms underlying this association and whether vitamin K supplementation improves peripheral VC severity.

Funding

  • Private Foundation Support